Dr. Lal PathLabs Limited
LALPATHLAB
Rank in Stocks
#4509
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health... Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to conducting pathological investigations across various specialized fields. These include biochemistry, hematology, histopathology, microbiology, electrophoresis, immunochemistry, immunology, virology, cytology, in addition to other general pathological and radiological studies. Beyond its core testing operations, Dr. Lal PathLabs also offers laboratory staff training, technical support, and full-scale lab management services. As of March 31, 2022, its widespread infrastructure included 277 clinical laboratories, notably a National Reference Lab located in Delhi and a Regional Reference Lab in Kolkata. This is further bolstered by 4,731 patient service centers and 10,599 sample collection points. Founded in 1949, Dr. Lal PathLabs Limited maintains its corporate base in Gurugram, India.
Share Price
$20.35
Last synced: 2026-10-19
Market Cap
$3.40B
Change (1 day)
-0.86%
Change (1 year)
13.63%
Country
IN
Trade Dr. Lal PathLabs Limited (LALPATHLAB)
Category
Healthcare
P/E ratio for Dr. Lal PathLabs Limited (LALPATHLAB)
P/E ratio as of October 2026 TTM: 57.71
According to Dr. Lal PathLabs Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 57.71. At the end of 2024 the company had a P/E ratio of 53.24.
P/E ratio history for Dr. Lal PathLabs Limited from 2011 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 57.71 | 40.44% |
| 2025 | 41.09 | -22.83% |
| 2024 | 53.24 | -16.09% |
| 2023 | 63.45 | 1.34% |
| 2022 | 62.61 | -18.29% |
| 2021 | 76.62 | 49.90% |
| 2020 | 51.12 | 17.78% |
| 2019 | 43.40 | 3.81% |
| 2018 | 41.81 | -18.03% |
| 2017 | 51.00 | -11.11% |
| 2016 | 57.38 | 21.27% |
| 2015 | 47.32 | -44.77% |
| 2014 | 85.67 | -30.73% |
| 2013 | 123.67 | -18.90% |
| 2012 | 152.48 | -34.87% |
| 2011 | 234.14 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | -37.35% |
US
|
|
| 39.77 | -31.08% |
US
|
|
| -290.26 | -602.99% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -40.76% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.